Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-08
DOI
10.1186/s12933-020-01199-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes
- (2020) Kausik K. Ray et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses
- (2019) Anup Dey et al. EMBO JOURNAL
- Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America
- (2019) Shannon M. Dunlay et al. CIRCULATION
- Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
- (2019) Laura M. Tsujikawa et al. Clinical Epigenetics
- Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation
- (2019) Matthew S. Stratton et al. CIRCULATION RESEARCH
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
- (2019) Kausik K. Ray et al. AMERICAN HEART JOURNAL
- Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis
- (2019) Jia-Li Feng et al. HEART FAILURE REVIEWS
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Apabetalone downregulates factors and pathways associated with vascular calcification
- (2018) Dean Gilham et al. ATHEROSCLEROSIS
- Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis
- (2018) Shuai Song et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction
- (2017) Kevin S. Shah et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure
- (2017) Qiming Duan et al. Science Translational Medicine
- Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
- (2017) Sylwia Wasiak et al. Journal of Cardiovascular Translational Research
- Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells
- (2017) Sadhan Das et al. Nature Communications
- RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
- (2016) Dean Gilham et al. ATHEROSCLEROSIS
- Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA
- (2016) Matthew S. Stratton et al. Cell Reports
- A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
- (2014) Ravi Jahagirdar et al. ATHEROSCLEROSIS
- NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
- (2014) Jonathan D. Brown et al. MOLECULAR CELL
- RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
- (2014) Kevin G. McLure et al. PLoS One
- BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
- (2013) Priti Anand et al. CELL
- BET acetyl-lysine binding proteins control pathological cardiac hypertrophy
- (2013) Jessica I. Spiltoir et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RVX-208
- (2010) Dana Bailey et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA
- (2008) B. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started